AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02816541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvis in Neutral Position
Description: Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
Study NCT02816541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercises (walking) performed on a treadmill.
Study NCT04045899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal LMA
Description: The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
Study NCT04045899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q LMA
Description: Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
Study NCT04045899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain LMA
Description: The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
Study NCT01687387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2102 at 0.1 mg/kg
Description: every 3 months
Study NCT01687387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2102 at 1 mg/kg
Description: every 4 weeks
Study NCT01687387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (normal saline solution)
Description: every 4 weeks
Study NCT01687387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline solution)
Description: every 4 weeks
Study NCT02424864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 4d PET-CT
Description: Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
Study NCT02073318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented balance training
Description: 4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
Study NCT02511340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib mesylate tablet 600 mg qd
Description: Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
Study NCT01540903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
Study NCT01540903 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study NCT04419649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
Study NCT03820869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Training
Description: Family Training
Study NCT03820869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational Therapy
Study NCT03233347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT03233347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study NCT03233347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03233347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03233347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03233347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study NCT02287740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance
Description: The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
Study NCT02287740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Exercise
Description: The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
Study NCT02287740 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching
Description: The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
Study NCT00409409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR grass pollen allergen extract tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study NCT02073318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremities exercise
Description: 4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks
Study NCT00925652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00925652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00925652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00925652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet
Study NCT00925652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: Diet+Exercise
Study NCT03186989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS MAPTRx
Description: Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48 weeks.
Study NCT03186989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks in Part 1. No placebo is given in Part 2.
Study NCT03348098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg, po, qd. 12weeks
Study NCT03348098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
Study NCT01116076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision+ program (to improve optimal drug prescription for ARI)
Description: DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
Study NCT02150070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: Intravenous (IV) infusion and subcutaneous (SC) injection
Study NCT02150070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion and Subcutaneous (SC) injection
Study NCT00862459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Description: Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Study NCT00862459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Description: Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Study NCT00862459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Description: Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Study NCT00862459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OptiMARK~0.1 mmol/kg BW
Description: Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Study NCT02547571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue diet
Study NCT01618916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC
Study NCT01618916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03212391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 52 weeks of Diet supervised by a dietician
Study NCT03212391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: 26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
Study NCT03212391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: 26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
Study NCT00553293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant luteinizing hormone (Luveris)
Description: 75 iu/day form cycle day 6
Study NCT00553293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant follicle stimulating hormone (Gonal-f)
Description: rFSH 150 iu/day
Study NCT04239443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)
Study NCT04239443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
Study NCT00236899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Study NCT00236899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Study NCT00236899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Study NCT02433899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICROSURGERY
Description: Semilunar coronally repositioned flap performed under magnification with a surgical microscope
Study NCT02433899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MACROSURGERY
Description: Semilunar coronally repositioned flap performed without magnification
Study NCT02433899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg Dexamethasone, single dose, 1 hour before surgery
Study NCT02433899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8mg Dexamethasone, single dose, 1 hour before surgery
Study NCT02433899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Oral rinses with chlorhexidine gluconate, BID, for 14 days
Study NCT02433899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Oral rinses with chlorhexidine gluconate, BID, for 14 days
Study NCT02433899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.0% Mepivacaine + 1:100.000 epinephrine
Description: Regional block
Study NCT02433899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0% Mepivacaine + 1:100.000 epinephrine
Description: Regional block
Study NCT01897766 — intervention group
Intervention type: DRUG
Intervention: Somatropin
Description: 0.23 mg to 0.48 mg/kg/week
Study NCT04339309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment with interdental hygiene devices
Study NCT04339309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment without interdental hygiene devices
Study NCT01226680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib
Description: 0.005% QD for 12 weeks
Study NCT01226680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib
Description: 0.003% QD for 12 weeks
Study NCT01226680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle for Tasocitinib
Description: vehicle QD for 12 weeks
Study NCT03904368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open myomectomy
Description: laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
Study NCT03904368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropin stimulation of follicular growth
Study NCT03904368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: HCG triggering of ovulation
Study NCT03904368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 to 36 hours after HCG triggering
Study NCT03904368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
Study NCT04275102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK
Description: Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
Study NCT00360802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Behavioral treatment to reduce pain in chronic back pain patients
Study NCT00360802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: Behavioral treatment to reduce pain in chronic back pain patients
Study NCT02178527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot and ankle exercises, foot orthoses, footwear provision
Description: Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
Study NCT02178527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual general podiatry care provded by UK National Health Service
Study NCT00655603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of native hormones from the pancreas and gut (GLP-1)
Description: Glucose-clamps at fasting levels during infusion of hormones in different combinations.
Study NCT05070468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.5mg
Description: Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
Study NCT05070468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
Study NCT02461797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: healthy controls
Description: biopsy of nasal mucosa for healthy controls
Study NCT02461797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AR patients without medication
Description: biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
Study NCT02461797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AR patients with use of nasal corticoid spray
Description: biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
Study NCT02109016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability.
Study NCT02484638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL689
Description: Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
Study NCT02547571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early colonoscopy (stratified)
Description: Early appointments: 7:30 AM to 10h30 AM
Study NCT02547571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Later colonoscopy (stratified)
Description: Later appointments: 10:30 AM to 4:30 PM.
Study NCT04396353 — intervention group
Intervention type: OTHER
Intervention: Electronic questionnaire
Description: Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
Study NCT00409409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study NCT02049515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: PI3K Inhibitor
Study NCT02049515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Monoclonal antibody
Study NCT04280562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sana Pain Reliever
Description: Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
Study NCT04280562 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SPR
Description: Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.